Researchers also associate ending GLP-1 therapy before pregnancy with a few risks.* Women who stopped taking a GLP-1 RA before or during early pregnancy had roughly 1.3x the risk of preterm birth, gestational diabetes, and high blood pressure conditions during pregnancy, compared to similar women who had not taken a GLP-1 RA
Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
In addition to diabetes and obesity, emerging data have demonstrated that GLP-1RAs reduce the rates of several other risk factors for PDAC (Fig
Whether your goal is to reduce your risk of chronic disease, improve mobility, boost energy, or simply feel better in your body, a medical-led plan can make the process safer and more effective
Starting early, applying a targeted body serum consistently, and pairing with a protein-rich diet and strength training gives your skin its best chance to firm, smooth, and adapt alongside your body
Emerging research is indicating that these meds may also create dysbiosis